(S)-naringenin multiple interactions ISO RGD:1350859 6480464 [naringenin metabolite co-treated with bisphenol A] results in increased expression of KRAS mRNA CTD PMID:36235125 (trichloromethyl)benzene increases mutagenesis ISO RGD:1550157 6480464 benzotrichloride results in increased mutagenesis of KRAS gene CTD PMID:8508514 1,1-dichloroethene increases expression ISO RGD:1550157 6480464 vinylidene chloride results in increased expression of KRAS mRNA CTD PMID:26682919 1,2-dimethylhydrazine affects expression ISO RGD:1550157 6480464 1, 2-Dimethylhydrazine affects the expression of KRAS mRNA CTD PMID:22206623 1,2-dimethylhydrazine multiple interactions ISO RGD:1550157 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of KRAS mRNA CTD PMID:22206623 1-nitropyrene increases mutagenesis ISO RGD:1550157 6480464 1-nitropyrene results in increased mutagenesis of KRAS gene CTD PMID:10396879 more ... 1-nitropyrene multiple interactions ISO RGD:1550157 6480464 [1-nitropyrene co-treated with KC 400] results in increased mutagenesis of KRAS gene more ... CTD PMID:10396879 more ... 17alpha-ethynylestradiol multiple interactions ISO RGD:1550157 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KRAS mRNA CTD PMID:17942748 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of KRAS mRNA CTD PMID:29097150 17beta-estradiol decreases expression ISO RGD:1350859 6480464 Estradiol results in decreased expression of KRAS mRNA CTD PMID:16474171 17beta-estradiol increases expression ISO RGD:1350859 6480464 Estradiol results in increased expression of KRAS mRNA CTD PMID:23094148 2,2-Bis(bromomethyl)propane-1,3-diol increases mutagenesis ISO RGD:1550157 6480464 2 more ... CTD PMID:14713543 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1350859 6480464 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA] CTD PMID:11007951 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of KRAS mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1550157 6480464 Tetrachlorodibenzodioxin affects the expression of KRAS mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1350859 6480464 Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA CTD PMID:11007951 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1350859 6480464 Tetrachlorodibenzodioxin affects the expression of KRAS mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1550157 6480464 Tetrachlorodibenzodioxin results in decreased expression of KRAS mRNA CTD PMID:14708085 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1550157 6480464 Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA CTD PMID:19465110 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1550157 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KRAS mRNA more ... CTD PMID:11884234 more ... 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of KRAS mRNA CTD PMID:21346803 2,6-di-tert-butyl-4-methylphenol increases mutagenesis ISO RGD:1550157 6480464 Butylated Hydroxytoluene results in increased mutagenesis of KRAS gene CTD PMID:20101149 2-trans,6-trans-farnesyl diphosphate multiple interactions EXP 6480464 [FNTA protein binds to FNTB protein] binds to [farnesyl pyrophosphate analog co-treated with KRAS protein] CTD PMID:10673434 3-methyl-3H-imidazo[4,5-f]quinolin-2-amine increases mutagenesis EXP 6480464 2-amino-3-methylimidazo(4, 5-f)quinoline results in increased mutagenesis of KRAS gene CTD PMID:8844820 3-methylcholanthrene multiple interactions ISO RGD:1550157 6480464 Methylcholanthrene promotes the reaction [GATA6 protein binds to KRAS exon], Methylcholanthrene promotes the reaction [NFYA protein binds to KRAS exon] CTD PMID:16271038 3-methylcholanthrene increases mutagenesis ISO RGD:1550157 6480464 Methylcholanthrene results in increased mutagenesis of KRAS gene CTD PMID:11195466 , PMID:20101149 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one increases mutagenesis EXP 6480464 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased mutagenesis of KRAS gene CTD PMID:18271921 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one multiple interactions ISO RGD:1550157 6480464 [Lipopolysaccharides co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased mutagenesis of KRAS gene CTD PMID:21868532 4-nitrophenol decreases expression ISO RGD:1550157 6480464 4-nitrophenol results in decreased expression of KRAS mRNA CTD PMID:34673133 4-vinylcyclohexene dioxide affects expression ISO RGD:1550157 6480464 4-vinyl-1-cyclohexene dioxide affects the expression of KRAS mRNA CTD PMID:20829426 5-aza-2'-deoxycytidine multiple interactions ISO RGD:1350859 6480464 Decitabine inhibits the reaction [arsenite results in increased expression of KRAS protein] CTD PMID:24704393 5-fluorouracil decreases expression ISO RGD:1350859 6480464 Fluorouracil results in decreased expression of KRAS protein CTD PMID:15585135 , PMID:16803524 5-Methylchrysene increases mutagenesis ISO RGD:1550157 6480464 5-methylchrysene results in increased mutagenesis of KRAS gene CTD PMID:8571376 , PMID:9659573 acrolein decreases expression ISO RGD:1350859 6480464 Acrolein results in decreased expression of KRAS protein CTD PMID:24812010 actinomycin D multiple interactions ISO RGD:1350859 6480464 Dactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA] CTD PMID:27222248 afimoxifene affects response to substance ISO RGD:1350859 6480464 KRAS gene affects the susceptibility to afimoxifene CTD PMID:21482774 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of KRAS mRNA CTD PMID:16483693 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of KRAS mRNA CTD PMID:30779732 antirheumatic drug decreases expression ISO RGD:1350859 6480464 Antirheumatic Agents results in decreased expression of KRAS mRNA CTD PMID:24449571 aristolochic acid A increases mutagenesis EXP 6480464 aristolochic acid I results in increased mutagenesis of KRAS gene CTD PMID:21642617 aristolochic acid A decreases expression ISO RGD:1350859 6480464 aristolochic acid I results in decreased expression of KRAS mRNA CTD PMID:33212167 Aroclor 1254 decreases expression ISO RGD:1550157 6480464 Chlorodiphenyl (54% Chlorine) results in decreased expression of KRAS mRNA, Chlorodiphenyl (54% Chlorine) results in decreased expression of KRAS protein CTD PMID:23650126 Aroclor 1254 affects localization ISO RGD:1550157 6480464 Chlorodiphenyl (54% Chlorine) affects the localization of KRAS protein CTD PMID:9525281 ARS-1620 affects binding ISO RGD:1350859 6480464 ARS-1620 binds to KRAS protein mutant form CTD PMID:31666701 arsane multiple interactions ISO RGD:1350859 6480464 KRAS affects the reaction [Arsenic results in increased phosphorylation of MAPK1 protein] more ... CTD PMID:25273566 arsane increases mutagenesis ISO RGD:1350859 6480464 Arsenic results in increased mutagenesis of KRAS gene CTD PMID:32344290 arsane affects response to substance ISO RGD:1350859 6480464 KRAS affects the susceptibility to Arsenic CTD PMID:25273566 arsenic atom multiple interactions ISO RGD:1350859 6480464 KRAS affects the reaction [Arsenic results in increased phosphorylation of MAPK1 protein] more ... CTD PMID:25273566 arsenic atom increases mutagenesis ISO RGD:1350859 6480464 Arsenic results in increased mutagenesis of KRAS gene CTD PMID:32344290 arsenic atom affects response to substance ISO RGD:1350859 6480464 KRAS affects the susceptibility to Arsenic CTD PMID:25273566 arsenite(3-) multiple interactions ISO RGD:1350859 6480464 decitabine inhibits the reaction [arsenite results in increased expression of KRAS protein], MIRLET7C mRNA inhibits the reaction [arsenite results in increased expression of KRAS protein] CTD PMID:24704393 arsenite(3-) increases mutagenesis ISO RGD:1350859 6480464 arsenite results in increased mutagenesis of KRAS gene mutant form CTD PMID:31009485 arsenite(3-) increases expression ISO RGD:1350859 6480464 arsenite results in increased expression of KRAS protein CTD PMID:24704393 asbestos increases mutagenesis ISO RGD:1350859 6480464 Asbestos results in increased mutagenesis of KRAS gene CTD PMID:12725029 Benz[j]aceanthrylene increases mutagenesis ISO RGD:1550157 6480464 benz(j)aceanthrylene results in increased mutagenesis of KRAS gene CTD PMID:9659573 benzene increases response to substance ISO RGD:1550157 6480464 KRAS gene polymorphism results in increased susceptibility to Benzene CTD PMID:12807761 benzo[a]pyrene increases expression ISO RGD:1550157 6480464 Benzo(a)pyrene results in increased expression of KRAS mRNA CTD PMID:22228805 benzo[a]pyrene affects methylation ISO RGD:1350859 6480464 Benzo(a)pyrene affects the methylation of KRAS promoter CTD PMID:27901495 benzo[a]pyrene increases mutagenesis ISO RGD:1550157 6480464 Benzo(a)pyrene results in increased mutagenesis of KRAS gene CTD PMID:19658153 more ... benzo[a]pyrene diol epoxide I increases expression ISO RGD:1350859 6480464 7 more ... CTD PMID:18567617 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1350859 6480464 7 more ... CTD PMID:19150397 , PMID:20018196 benzo[b]fluoranthene increases mutagenesis ISO RGD:1550157 6480464 benzo(b)fluoranthene results in increased mutagenesis of KRAS gene CTD PMID:8571376 , PMID:9659573 bisphenol A decreases expression ISO RGD:1350859 6480464 bisphenol A results in decreased expression of KRAS mRNA CTD PMID:16474171 bisphenol A multiple interactions ISO RGD:1350859 6480464 [naringenin metabolite co-treated with bisphenol A] results in increased expression of KRAS mRNA CTD PMID:36235125 bisphenol A decreases expression ISO RGD:1550157 6480464 bisphenol A results in decreased expression of KRAS mRNA CTD PMID:33221593 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of KRAS gene CTD PMID:28505145 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of KRAS mRNA CTD PMID:29097150 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of KRAS mRNA CTD PMID:25181051 bisphenol A increases expression ISO RGD:1550157 6480464 bisphenol A results in increased expression of KRAS mRNA CTD PMID:26063408 bisphenol A increases mutagenesis ISO RGD:1350859 6480464 bisphenol A results in increased mutagenesis of KRAS gene CTD PMID:11342245 bleomycin A2 multiple interactions ISO RGD:1550157 6480464 [Bleomycin co-treated with 1-nitropyrene] results in increased mutagenesis of KRAS gene CTD PMID:12616606 buta-1,3-diene increases mutagenesis ISO RGD:1550157 6480464 1, 3-butadiene results in increased mutagenesis of KRAS gene CTD PMID:11397402 cadmium atom increases expression ISO RGD:1350859 6480464 Cadmium results in increased expression of KRAS mRNA, Cadmium results in increased expression of KRAS protein CTD PMID:20049202 cadmium atom decreases expression ISO RGD:1350859 6480464 Cadmium results in decreased expression of KRAS mRNA CTD PMID:21120746 cadmium dichloride decreases expression EXP 6480464 Cadmium Chloride results in decreased expression of KRAS mRNA CTD PMID:33453195 cadmium dichloride multiple interactions ISO RGD:1350859 6480464 KRAS protein inhibits the reaction [Cadmium Chloride results in decreased expression of MIR155 mRNA] more ... CTD PMID:27510461 cadmium dichloride increases expression ISO RGD:1350859 6480464 Cadmium Chloride results in increased expression of KRAS mRNA, Cadmium Chloride results in increased expression of KRAS protein CTD PMID:23811327 more ... cannabidiol decreases expression EXP 6480464 Cannabidiol results in decreased expression of KRAS mRNA CTD PMID:32553926 cannabidiol multiple interactions ISO RGD:1350859 6480464 [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of KRAS mRNA CTD PMID:32992648 carbamazepine affects expression ISO RGD:1350859 6480464 Carbamazepine affects the expression of KRAS mRNA CTD PMID:24752500 carbon nanotube increases mutagenesis ISO RGD:1550157 6480464 Nanotubes, Carbon results in increased mutagenesis of KRAS gene CTD PMID:24213921 ceruletide multiple interactions ISO RGD:1550157 6480464 (+)-JQ1 compound inhibits the reaction [[KRAS protein mutant form co-treated with Ceruletide] results in increased expression of BRD4 protein] more ... CTD PMID:26390243 CGP 52608 multiple interactions ISO RGD:1350859 6480464 CGP 52608 promotes the reaction [RORA protein binds to KRAS gene] CTD PMID:28238834 chloroethene multiple interactions ISO RGD:1350859 6480464 CYP2E1 gene polymorphism promotes the reaction [Vinyl Chloride affects the mutagenesis of KRAS gene] more ... CTD PMID:12705718 more ... chloroethene increases mutagenesis ISO RGD:1350859 6480464 Vinyl Chloride results in increased mutagenesis of KRAS gene CTD PMID:10629081 more ... chloroethene increases response to substance ISO RGD:1550157 6480464 KRAS gene polymorphism results in increased susceptibility to Vinyl Chloride CTD PMID:12807761 chloroprene increases mutagenesis ISO RGD:1550157 6480464 Chloroprene results in increased mutagenesis of KRAS gene CTD PMID:10223196 , PMID:11397402 chlorpyrifos decreases expression EXP 6480464 Chlorpyrifos results in decreased expression of KRAS mRNA CTD PMID:18668222 chymostatin multiple interactions ISO RGD:1350859 6480464 chymostatin inhibits the reaction [KRAS protein mutant form results in increased expression of AGT protein] more ... CTD PMID:33380422 cisplatin multiple interactions ISO RGD:1350859 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of KRAS mRNA CTD PMID:27392435 cisplatin decreases expression ISO RGD:1350859 6480464 Cisplatin results in decreased expression of KRAS mRNA CTD PMID:27392435 clofibrate increases expression ISO RGD:1550157 6480464 Clofibrate results in increased expression of KRAS mRNA CTD PMID:23811191 cobalt atom increases mutagenesis EXP 6480464 Cobalt results in increased mutagenesis of KRAS gene CTD PMID:34468815 cobalt atom increases mutagenesis ISO RGD:1550157 6480464 Cobalt results in increased mutagenesis of KRAS gene CTD PMID:34468815 cobimetinib increases response to substance ISO RGD:1350859 6480464 KRAS protein mutant form results in increased susceptibility to cobimetinib CTD PMID:22084396 cobimetinib multiple interactions ISO RGD:1350859 6480464 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3 more ... CTD PMID:22084396 copper atom increases expression EXP 6480464 Copper deficiency results in increased expression of KRAS mRNA, Copper results in increased expression of KRAS mRNA CTD PMID:17418555 , PMID:22465980 copper atom multiple interactions ISO RGD:1350859 6480464 [Chelating Agents binds to Copper] which results in increased expression of KRAS mRNA CTD PMID:30911355 copper(0) increases expression EXP 6480464 Copper deficiency results in increased expression of KRAS mRNA, Copper results in increased expression of KRAS mRNA CTD PMID:17418555 , PMID:22465980 copper(0) multiple interactions ISO RGD:1350859 6480464 [Chelating Agents binds to Copper] which results in increased expression of KRAS mRNA CTD PMID:30911355 coumestrol decreases expression ISO RGD:1350859 6480464 Coumestrol results in decreased expression of KRAS mRNA CTD PMID:19167446 crizotinib decreases response to substance ISO RGD:1350859 6480464 KRAS protein mutant form results in decreased susceptibility to crizotinib CTD PMID:22235099 cumene multiple interactions ISO RGD:1550157 6480464 [cumene co-treated with KRAS gene mutant form] results in decreased expression of CCN1 mRNA more ... CTD PMID:18648096 Cuprizon decreases expression EXP 6480464 Cuprizone results in decreased expression of KRAS mRNA CTD PMID:26577399 curcumin decreases expression ISO RGD:1350859 6480464 Curcumin analog results in decreased expression of KRAS mRNA, Curcumin results in decreased expression of KRAS mRNA CTD PMID:17041101 curcumin multiple interactions ISO RGD:1550157 6480464 Curcumin affects the reaction [KRAS protein affects the localization of TRP53 protein], Curcumin inhibits the reaction [KRAS protein results in decreased expression of XPO1 protein] CTD PMID:21519798 cycloheximide multiple interactions ISO RGD:1350859 6480464 Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA] CTD PMID:11007951 Cyclopenta[cd]pyrene increases mutagenesis ISO RGD:1550157 6480464 cyclopenta(c, d)pyrene results in increased mutagenesis of KRAS gene CTD PMID:9659573 dabrafenib multiple interactions ISO RGD:1350859 6480464 [KRAS protein affects the susceptibility to dabrafenib] which affects the expression of TNFRSF10B protein more ... CTD PMID:27222248 dabrafenib affects response to substance ISO RGD:1350859 6480464 KRAS protein affects the susceptibility to dabrafenib CTD PMID:27222248 dextran sulfate multiple interactions ISO RGD:1550157 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KRAS mRNA, Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of KRAS protein] CTD PMID:29950665 , PMID:32272095 dextran sulfate decreases expression ISO RGD:1550157 6480464 Dextran Sulfate results in decreased expression of KRAS protein CTD PMID:32272095 dibenzo[a,l]pyrene increases mutagenesis ISO RGD:1550157 6480464 dibenzo(a, l)pyrene results in increased mutagenesis of KRAS gene CTD PMID:9659573 dichlorine multiple interactions EXP 6480464 [Ozone co-treated with Chlorine] results in decreased expression of KRAS mRNA CTD PMID:18636392 diclofenac affects expression ISO RGD:1350859 6480464 Diclofenac affects the expression of KRAS mRNA CTD PMID:24752500 dioxygen multiple interactions ISO RGD:1350859 6480464 [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of KRAS mRNA, [Oxygen co-treated with Ozone] results in decreased expression of KRAS mRNA CTD PMID:32992648 dorsomorphin multiple interactions ISO RGD:1350859 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1350859 6480464 Doxorubicin results in decreased expression of KRAS mRNA CTD PMID:29803840 erlotinib hydrochloride increases response to substance ISO RGD:1350859 6480464 KRAS protein results in increased susceptibility to Erlotinib Hydrochloride CTD PMID:20705357 ethanol affects splicing ISO RGD:1550157 6480464 Ethanol affects the splicing of KRAS mRNA CTD PMID:30319688 farnesyl diphosphate multiple interactions EXP 6480464 [FNTA protein binds to FNTB protein] binds to [farnesyl pyrophosphate analog co-treated with KRAS protein] CTD PMID:10673434 flutamide increases expression EXP 6480464 Flutamide results in increased expression of KRAS mRNA CTD PMID:24136188 folic acid increases expression ISO RGD:1550157 6480464 Folic Acid results in increased expression of KRAS mRNA CTD PMID:2566606 folic acid multiple interactions ISO RGD:1550157 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of KRAS mRNA CTD PMID:22206623 folic acid decreases expression ISO RGD:1550157 6480464 Folic Acid results in decreased expression of KRAS mRNA CTD PMID:25629700 GDP multiple interactions ISO RGD:1350859 6480464 KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]], SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein] CTD PMID:28154176 GDP affects binding ISO RGD:1350859 6480464 Guanosine Diphosphate binds to KRAS protein, Guanosine Diphosphate binds to KRAS protein mutant form CTD PMID:28154176 gefitinib affects response to substance ISO RGD:1350859 6480464 KRAS protein mutant form affects the susceptibility to gefitinib CTD PMID:17270025 gefitinib decreases response to substance ISO RGD:1350859 6480464 KRAS protein results in decreased susceptibility to gefitinib CTD PMID:28739874 gefitinib multiple interactions ISO RGD:1350859 6480464 KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib] CTD PMID:28739874 genistein decreases expression ISO RGD:1350859 6480464 Genistein results in decreased expression of KRAS mRNA CTD PMID:15256057 , PMID:16474171 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of KRAS mRNA CTD PMID:22061828 geraniol multiple interactions EXP 6480464 geraniol inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of KRAS mRNA] CTD PMID:28428697 GTP multiple interactions ISO RGD:1350859 6480464 KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]], RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate] CTD PMID:28154176 GTP affects binding ISO RGD:1350859 6480464 Guanosine Triphosphate binds to KRAS protein, Guanosine Triphosphate binds to KRAS protein mutant form CTD PMID:28154176 GTP increases hydrolysis ISO RGD:1350859 6480464 KRAS protein mutant form results in increased hydrolysis of Guanosine Triphosphate, KRAS protein results in increased hydrolysis of Guanosine Triphosphate CTD PMID:28154176 guanosine multiple interactions ISO RGD:1350859 6480464 Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS] CTD PMID:9381980 haloperidol increases expression EXP 6480464 Haloperidol results in increased expression of KRAS mRNA CTD PMID:15860345 hydrogen peroxide multiple interactions ISO RGD:1550157 158013773 melatonin inhibits the reaction [hydrogen peroxide increases expression of Kras protein in C-kit+ cardiac progenitor cells] RGD hydrogen peroxide increases expression ISO RGD:1550157 158013773 hydrogen peroxide increases expression of Kras protein in C-kit+ cardiac progenitor cells RGD hydroquinone multiple interactions ISO RGD:1350859 6480464 [PARP1 protein affects the susceptibility to hydroquinone] which affects the expression of KRAS protein CTD PMID:28444915 hydroquinone increases expression ISO RGD:1350859 6480464 hydroquinone results in increased expression of KRAS protein CTD PMID:27515134 hydroquinone affects expression ISO RGD:1350859 6480464 hydroquinone affects the expression of KRAS mRNA CTD PMID:27515134 hydroxyurea decreases expression ISO RGD:1550157 6480464 Hydroxyurea results in decreased expression of KRAS mRNA CTD PMID:12929121 ionomycin multiple interactions ISO RGD:1350859 6480464 Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] more ... CTD PMID:15263067 irbesartan multiple interactions ISO RGD:1550157 6480464 Irbesartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN2A protein] CTD PMID:33380422 irbesartan multiple interactions ISO RGD:1350859 6480464 Irbesartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN1A protein] CTD PMID:33380422 isoprenaline increases expression ISO RGD:1550157 6480464 Isoproterenol results in increased expression of KRAS mRNA CTD PMID:21335049 isoprene increases mutagenesis ISO RGD:1550157 6480464 isoprene results in increased mutagenesis of KRAS gene CTD PMID:11397402 , PMID:9111215 isotretinoin decreases expression ISO RGD:1350859 6480464 Isotretinoin results in decreased expression of KRAS mRNA CTD PMID:20436886 ivermectin decreases expression ISO RGD:1350859 6480464 Ivermectin results in decreased expression of KRAS protein CTD PMID:32959892 kainic acid increases expression EXP 6480464 Kainic Acid results in increased expression of KRAS mRNA CTD PMID:19700661 lapatinib multiple interactions ISO RGD:1350859 6480464 KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib] CTD PMID:28739874 lapatinib decreases response to substance ISO RGD:1350859 6480464 KRAS protein results in decreased susceptibility to lapatinib CTD PMID:28739874 lead diacetate decreases expression ISO RGD:1550157 6480464 lead acetate results in decreased expression of KRAS mRNA CTD PMID:21829687 lead diacetate multiple interactions ISO RGD:1350859 6480464 [lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA CTD PMID:22839698 lead diacetate increases expression ISO RGD:1550157 6480464 lead acetate results in increased expression of KRAS mRNA CTD PMID:25270620 lead(0) increases expression ISO RGD:1550157 6480464 Lead results in increased expression of KRAS protein CTD PMID:19727529 lead(2+) increases expression ISO RGD:1550157 6480464 Lead results in increased expression of KRAS protein CTD PMID:19727529 lipopolysaccharide multiple interactions ISO RGD:1550157 6480464 [Lipopolysaccharides co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased mutagenesis of KRAS gene CTD PMID:21868532 lipopolysaccharide increases expression ISO RGD:1350859 6480464 Lipopolysaccharides results in increased expression of KRAS mRNA CTD PMID:35953652 losartan multiple interactions ISO RGD:1350859 6480464 Losartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN1A protein], Losartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN2A protein] CTD PMID:33380422 lovastatin decreases prenylation ISO RGD:1350859 6480464 Lovastatin results in decreased prenylation of KRAS protein CTD PMID:16156861 lovastatin increases expression ISO RGD:1550157 6480464 Lovastatin results in increased expression of KRAS protein CTD PMID:12907238 lovastatin affects localization ISO RGD:1550157 6480464 Lovastatin affects the localization of KRAS protein CTD PMID:12106604 lovastatin increases activity ISO RGD:1550157 6480464 Lovastatin results in increased activity of KRAS protein CTD PMID:17005160 luzindole multiple interactions ISO RGD:1550157 158013773 luzindole inhibits the reaction [melatonin inhibits the reaction [hydrogen peroxide increases expression of Kras protein in C-kit+ cardiac progenitor cells]] RGD manumycin A multiple interactions ISO RGD:1350859 6480464 Acetylcysteine inhibits the reaction [manumycin results in decreased activity of KRAS protein] CTD PMID:19409983 manumycin A decreases activity ISO RGD:1350859 6480464 manumycin results in decreased activity of KRAS protein CTD PMID:19409983 MeIQx increases mutagenesis EXP 6480464 2-amino-3 more ... CTD PMID:18271921 mercury dibromide decreases expression ISO RGD:1350859 6480464 mercuric bromide results in decreased expression of KRAS mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1350859 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA CTD PMID:27188386 metformin multiple interactions ISO RGD:1350859 6480464 [Paclitaxel co-treated with Metformin] results in decreased expression of KRAS mRNA CTD PMID:29309887 methohexital multiple interactions ISO RGD:1350859 6480464 Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] CTD PMID:15263067 methotrexate increases response to substance ISO RGD:1350859 6480464 KRAS gene mutant form results in increased susceptibility to Methotrexate CTD PMID:24688052 methotrexate decreases expression ISO RGD:1350859 6480464 Methotrexate results in decreased expression of KRAS mRNA more ... CTD PMID:24688052 monosodium L-glutamate decreases expression EXP 6480464 Sodium Glutamate results in decreased expression of KRAS mRNA CTD PMID:20928830 N,N-bis(2-hydroxypropyl)nitrosamine increases mutagenesis EXP 6480464 diisopropanolnitrosamine results in increased mutagenesis of KRAS gene CTD PMID:18271921 N-acetyl-L-cysteine multiple interactions ISO RGD:1350859 6480464 Acetylcysteine inhibits the reaction [manumycin results in decreased activity of KRAS protein] CTD PMID:19409983 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression ISO RGD:1350859 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KRAS mRNA CTD PMID:31806706 N-ethyl-N-nitrosourea multiple interactions ISO RGD:1550157 6480464 Ethylnitrosourea promotes the reaction [GATA6 protein binds to KRAS exon], Ethylnitrosourea promotes the reaction [NFYA protein binds to KRAS exon] CTD PMID:16271038 N-ethyl-N-nitrosourea increases mutagenesis ISO RGD:1550157 6480464 Ethylnitrosourea results in increased mutagenesis of KRAS gene CTD PMID:15790496 N-methyl-N'-nitro-N-nitrosoguanidine multiple interactions EXP 6480464 geraniol inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of KRAS mRNA] CTD PMID:28428697 N-methyl-N'-nitro-N-nitrosoguanidine increases expression EXP 6480464 Methylnitronitrosoguanidine results in increased expression of KRAS mRNA CTD PMID:28428697 N-methyl-N-nitrosourea decreases response to substance EXP 6480464 KRAS protein results in decreased susceptibility to Methylnitrosourea CTD PMID:11973638 N-methyl-N-nitrosourea increases mutagenesis ISO RGD:1550157 6480464 Methylnitrosourea results in increased mutagenesis of KRAS gene CTD PMID:12483526 , PMID:18062963 N-nitrosodiethylamine increases expression EXP 6480464 Diethylnitrosamine results in increased expression of KRAS mRNA CTD PMID:7910516 N-nitrosodiethylamine increases expression ISO RGD:1550157 6480464 Diethylnitrosamine results in increased expression of KRAS mRNA CTD PMID:26464624 N-nitrosodimethylamine affects localization ISO RGD:1550157 6480464 Dimethylnitrosamine affects the localization of KRAS protein CTD PMID:11884234 N-nitrosodimethylamine multiple interactions ISO RGD:1550157 6480464 Dimethylnitrosamine results in decreased expression of and affects the localization of KRAS protein more ... CTD PMID:11884234 , PMID:19555203 nicotinic acid affects localization ISO RGD:1550157 6480464 Niacin affects the localization of KRAS protein CTD PMID:12106604 ochratoxin A decreases expression ISO RGD:1350859 6480464 ochratoxin A results in decreased expression of KRAS mRNA CTD PMID:30559759 oncrasin-1 increases response to substance ISO RGD:1350859 6480464 KRAS protein mutant form results in increased susceptibility to oncrasin-1 CTD PMID:21443218 oxirane increases mutagenesis ISO RGD:1550157 6480464 Ethylene Oxide results in increased mutagenesis of KRAS gene CTD PMID:24029818 ozone multiple interactions EXP 6480464 [Ozone co-treated with Chlorine] results in decreased expression of KRAS mRNA CTD PMID:18636392 ozone multiple interactions ISO RGD:1350859 6480464 [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of KRAS mRNA, [Oxygen co-treated with Ozone] results in decreased expression of KRAS mRNA CTD PMID:32992648 ozone increases expression EXP 6480464 Ozone results in increased expression of KRAS mRNA CTD PMID:16330353 p-chloromercuribenzoic acid decreases expression ISO RGD:1350859 6480464 p-Chloromercuribenzoic Acid results in decreased expression of KRAS mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:1350859 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA CTD PMID:27188386 paclitaxel multiple interactions ISO RGD:1350859 6480464 [Paclitaxel co-treated with Metformin] results in decreased expression of KRAS mRNA CTD PMID:29309887 paracetamol affects expression ISO RGD:1550157 6480464 Acetaminophen affects the expression of KRAS mRNA CTD PMID:17562736 PD 0325901 multiple interactions ISO RGD:1550157 6480464 [mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein] CTD PMID:24576621 PD 0325901 multiple interactions ISO RGD:1350859 6480464 KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]] more ... CTD PMID:24576621 pemetrexed increases response to substance ISO RGD:1350859 6480464 KRAS gene mutant form results in increased susceptibility to Pemetrexed CTD PMID:24688052 pemetrexed decreases expression ISO RGD:1350859 6480464 Pemetrexed results in decreased expression of KRAS mRNA more ... CTD PMID:24688052 pentobarbital multiple interactions ISO RGD:1350859 6480464 Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] CTD PMID:15263067 phlorizin decreases expression ISO RGD:1550157 6480464 Phlorhizin results in decreased expression of KRAS mRNA CTD PMID:22538082 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1350859 6480464 Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] more ... CTD PMID:15263067 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1550157 6480464 [sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS mRNA, [sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS protein CTD PMID:16368122 picrotoxin decreases expression EXP 6480464 Picrotoxin results in decreased expression of KRAS mRNA CTD PMID:15170462 piperonyl butoxide increases mutagenesis ISO RGD:1350859 6480464 Piperonyl Butoxide results in increased mutagenesis of KRAS gene CTD PMID:7565889 pirinixic acid multiple interactions ISO RGD:1350859 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of KRAS mRNA CTD PMID:19710929 quercetin multiple interactions ISO RGD:1350859 6480464 Quercetin inhibits the reaction [KRAS protein affects the activity of TP53 protein] CTD PMID:19424582 quercetin decreases expression ISO RGD:1350859 6480464 Quercetin results in decreased expression of KRAS mRNA, Quercetin results in decreased expression of KRAS protein CTD PMID:10652438 , PMID:9381980 Rebamipide increases expression EXP 6480464 rebamipide results in increased expression of KRAS mRNA CTD PMID:18299717 resveratrol decreases expression ISO RGD:1350859 6480464 resveratrol results in decreased expression of KRAS mRNA, resveratrol results in decreased expression of KRAS protein CTD PMID:12002526 more ... resveratrol multiple interactions ISO RGD:1350859 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of KRAS mRNA CTD PMID:23557933 resveratrol decreases expression ISO RGD:1550157 6480464 resveratrol results in decreased expression of KRAS protein mutant form CTD PMID:25280562 riddelliine increases mutagenesis ISO RGD:1550157 6480464 riddelliine results in increased mutagenesis of KRAS gene CTD PMID:13678655 , PMID:20737008 SB 431542 multiple interactions ISO RGD:1350859 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 secobarbital multiple interactions ISO RGD:1350859 6480464 Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] CTD PMID:15263067 selumetinib multiple interactions ISO RGD:1350859 6480464 AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]] more ... CTD PMID:27222248 sevoflurane decreases expression ISO RGD:1350859 6480464 Sevoflurane results in decreased expression of KRAS mRNA CTD PMID:35953652 simvastatin decreases prenylation ISO RGD:1350859 6480464 Simvastatin results in decreased prenylation of KRAS protein CTD PMID:8063617 sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of KRAS mRNA CTD PMID:11241755 sodium arsenite multiple interactions ISO RGD:1550157 6480464 [sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS mRNA, [sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of KRAS protein CTD PMID:16368122 sodium arsenite affects expression ISO RGD:1350859 6480464 sodium arsenite affects the expression of KRAS protein CTD PMID:17384772 sodium arsenite affects expression ISO RGD:1550157 6480464 sodium arsenite affects the expression of KRAS mRNA CTD PMID:16507464 sodium arsenite increases expression ISO RGD:1350859 6480464 sodium arsenite results in increased expression of KRAS protein CTD PMID:24431212 , PMID:25804888 sodium arsenite increases expression ISO RGD:1550157 6480464 sodium arsenite results in increased expression of KRAS mRNA, sodium arsenite results in increased expression of KRAS protein CTD PMID:16014739 , PMID:16507464 Soman increases expression EXP 6480464 Soman results in increased expression of KRAS mRNA CTD PMID:19281266 sotorasib increases response to substance ISO RGD:1350859 6480464 KRAS protein mutant form results in increased susceptibility to sotorasib CTD PMID:31666701 sotorasib affects binding ISO RGD:1350859 6480464 sotorasib binds to KRAS protein mutant form CTD PMID:31666701 sotorasib multiple interactions ISO RGD:1350859 6480464 KRAS protein affects the reaction [sotorasib results in decreased phosphorylation of MAPK1 protein], KRAS protein affects the reaction [sotorasib results in decreased phosphorylation of MAPK3 protein] CTD PMID:31666701 styrene increases response to substance ISO RGD:1550157 6480464 KRAS gene polymorphism results in increased susceptibility to Styrene CTD PMID:12807761 sulfur dioxide increases expression EXP 6480464 Sulfur Dioxide results in increased expression of KRAS mRNA, Sulfur Dioxide results in increased expression of KRAS protein CTD PMID:19434695 sulindac affects response to substance ISO RGD:1350859 6480464 KRAS protein affects the susceptibility to Sulindac CTD PMID:11751493 tacrolimus hydrate increases expression ISO RGD:1550157 6480464 Tacrolimus results in increased expression of KRAS mRNA CTD PMID:25270620 Tanshinone I decreases response to substance ISO RGD:1350859 6480464 KRAS mRNA results in decreased susceptibility to tanshinone CTD PMID:30506648 Tanshinone I decreases expression ISO RGD:1350859 6480464 tanshinone results in decreased expression of KRAS mRNA, tanshinone results in decreased expression of KRAS protein CTD PMID:30506648 Temsirolimus decreases response to substance ISO RGD:1350859 6480464 KRAS protein mutant form results in decreased susceptibility to temsirolimus CTD PMID:24493623 Temsirolimus multiple interactions ISO RGD:1350859 6480464 KRAS protein mutant form inhibits the reaction [temsirolimus inhibits the reaction [CIP2A protein binds to MTOR protein]] more ... CTD PMID:24493623 testosterone enanthate affects expression ISO RGD:1350859 6480464 testosterone enanthate affects the expression of KRAS mRNA CTD PMID:17440010 tetrachloromethane affects expression ISO RGD:1550157 6480464 Carbon Tetrachloride affects the expression of KRAS mRNA CTD PMID:17484886 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of KRAS mRNA CTD PMID:33387578 tetrachloromethane increases expression ISO RGD:1550157 6480464 Carbon Tetrachloride results in increased expression of KRAS mRNA CTD PMID:31919559 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of KRAS mRNA CTD PMID:31150632 , PMID:8847708 Tetranitromethane increases mutagenesis ISO RGD:1550157 6480464 Tetranitromethane results in increased mutagenesis of KRAS gene CTD PMID:14713543 thiamylal multiple interactions ISO RGD:1350859 6480464 Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] CTD PMID:15263067 thimerosal decreases expression ISO RGD:1350859 6480464 Thimerosal results in decreased expression of KRAS mRNA CTD PMID:27188386 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of KRAS mRNA CTD PMID:34492290 tiazofurine multiple interactions ISO RGD:1350859 6480464 Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS] CTD PMID:9381980 tiazofurine decreases expression ISO RGD:1350859 6480464 tiazofurin results in decreased expression of KRAS CTD PMID:9381980 tipifarnib increases expression EXP 6480464 tipifarnib results in increased expression of KRAS mRNA CTD PMID:16403772 titanium dioxide decreases expression ISO RGD:1550157 6480464 titanium dioxide results in decreased expression of KRAS mRNA CTD PMID:23557971 titanium dioxide multiple interactions ISO RGD:1550157 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KRAS mRNA CTD PMID:29950665 titanium dioxide affects expression ISO RGD:1550157 6480464 titanium dioxide affects the expression of KRAS mRNA CTD PMID:17656681 toluene affects expression EXP 6480464 Toluene affects the expression of KRAS mRNA CTD PMID:21827849 trimetrexate increases response to substance ISO RGD:1350859 6480464 KRAS gene mutant form results in increased susceptibility to Trimetrexate CTD PMID:24688052 Triptolide increases expression EXP 6480464 triptolide results in increased expression of KRAS mRNA CTD PMID:23639586 triptonide increases expression ISO RGD:1550157 6480464 triptonide results in increased expression of KRAS mRNA CTD PMID:33045310 urethane affects response to substance ISO RGD:1550157 6480464 KRAS gene affects the susceptibility to Urethane CTD PMID:11807781 urethane decreases expression ISO RGD:1350859 6480464 Urethane results in decreased expression of KRAS mRNA CTD PMID:28818685 urethane increases mutagenesis ISO RGD:1550157 6480464 Urethane results in increased mutagenesis of KRAS gene CTD PMID:10779650 urethane increases mutagenesis EXP 6480464 Urethane results in increased mutagenesis of KRAS gene CTD PMID:18271921 urethane decreases expression ISO RGD:1550157 6480464 Urethane results in decreased expression of KRAS mRNA CTD PMID:16289808 ursodeoxycholic acid multiple interactions EXP 6480464 Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased mutagenesis of KRAS gene] CTD PMID:12839936 valproic acid increases expression ISO RGD:1350859 6480464 Valproic Acid results in increased expression of KRAS mRNA CTD PMID:28001369 vemurafenib affects response to substance ISO RGD:1350859 6480464 KRAS protein mutant form affects the susceptibility to vemurafenib CTD PMID:27222248 vemurafenib multiple interactions ISO RGD:1350859 6480464 [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein] more ... CTD PMID:27222248 vinyl carbamate multiple interactions ISO RGD:1550157 6480464 diallyl sulfone inhibits the reaction [vinyl carbamate results in increased mutagenesis of KRAS gene] CTD PMID:20205516 vinyl carbamate increases mutagenesis ISO RGD:1550157 6480464 vinyl carbamate results in increased mutagenesis of KRAS gene CTD PMID:20205516 zearalenone decreases expression ISO RGD:1550157 6480464 Zearalenone results in decreased expression of KRAS mRNA CTD PMID:30717214 zearalenone increases expression ISO RGD:1550157 6480464 Zearalenone results in increased expression of KRAS mRNA CTD PMID:29758222 zidovudine increases mutagenesis ISO RGD:1550157 6480464 Zidovudine results in increased mutagenesis of KRAS gene CTD PMID:18800350 zinc protoporphyrin multiple interactions ISO RGD:1350859 6480464 [lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA CTD PMID:22839698 zoledronic acid increases expression ISO RGD:1350859 6480464 zoledronic acid results in increased expression of KRAS protein CTD PMID:28871336